Romlusevimab
Based on 1 Customer Validation
Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 95.00%
- CAS 番号: 2509447-08-7
- 分子量:145.126 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
Human IgG1 lambda2
Virus
Severe acute respiratory syndrome coronavirus 2
Romlusevimab and Amubarvimab (HY-P99435) bind to distinct epitopes of the SARS-CoV-2 spike protein[1].
Romlusevimab has an additive effect when combined with Amubarvimab[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
43740600 [NCBI]
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 lambda2
ELISA, FACS, Functional assay
化学情報
-
CAS 番号 2509447-08-7
-
性状 Liquid
-
分子量 145.126 kDa
-
Color Colorless to light yellow
-
SMILES
[Romlusevimab]
-
別名
BRII-198
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drugs. 2022 Aug;82(12):1327-1331. [Content Brief]
[2]. Ji Y, et al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Romlusevimab 関連分類
HY-P99889 関連分類
Powered by Bioz